Ampio Pharmaceuticals (AMPE +4%) trades up after announcing its begun dosing the first patient...


Ampio Pharmaceuticals (AMPE +4%) trades up after announcing its begun dosing the first patient in its clinical trial of Optina, a treatment for diabetic macular edema. The trial will evaluate the drug in adults with recent onset of the disease. Last year, the FDA granted Optina 505(b)(2) status. Drugs under this designated pathway can be approved on a single trial.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs